Hydrochlorothiazide (DCT) antibody and antigen (hapten, BSA/OVA conjugated)

 Download 

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-SMT-207-Ag01	BSA-Hydrochlorothiazide (DCT)	756
GMP-SMT-207-Ag02	OVA-Hydrochlorothiazide (DCT)	756
GMP-SMT-207-Ab01	Anti-human Hydrochlorothiazide (DCT) mouse monoclonal antibody (mAb)	1953
GMP-SMT-207-Ab02	Anti-human Hydrochlorothiazide (DCT) human monoclonal antibody (mAb)	1953

Size： 1mg | 10mg | 100mg

Product Description

Cat No. of Products	GMP-SMT-207-Ag01
Product Name	BSA-Hydrochlorothiazide (DCT)
Target/Biomarker	Hydrochlorothiazide (DCT)
Expression platform	Synthetic
Isotypes	NA
Bioactivity validation	Hydrochlorothiazide (DCT) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in DCT level test of Cardiovascular disease (high blood pressure) and related syndrome evaluation.
Tag	NA
Products description	Competitive immunoassay-validated hapten-carrier conjugates BSA-Hydrochlorothiazide (DCT) / OVA-Hydrochlorothiazide (DCT) is Synthetic.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-SMT-207-Ag02
Product Name	OVA-Hydrochlorothiazide (DCT)
Target/Biomarker	Hydrochlorothiazide (DCT)
Expression platform	Synthetic
Isotypes	NA
Bioactivity validation	Hydrochlorothiazide (DCT) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in DCT level test of Cardiovascular disease (high blood pressure) and related syndrome evaluation.
Tag	NA
Products description	Competitive immunoassay-validated hapten-carrier conjugates BSA-Hydrochlorothiazide (DCT) / OVA-Hydrochlorothiazide (DCT) is Synthetic.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-SMT-207-Ab01
Product Name	Anti-human Hydrochlorothiazide (DCT) mouse monoclonal antibody (mAb)
Target/Biomarker	Hydrochlorothiazide (DCT)
Expression platform	Hybridoma
Isotypes	Mouse IgG
Bioactivity validation	Hydrochlorothiazide (DCT) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in DCT level test of Cardiovascular disease (high blood pressure) and related syndrome evaluation.
Tag	mFc
Products description	Competitive immunoassay-validated hapten-carrier conjugates BSA-Hydrochlorothiazide (DCT) / OVA-Hydrochlorothiazide (DCT) is Synthetic.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA),Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-SMT-207-Ab02
Product Name	Anti-human Hydrochlorothiazide (DCT) human monoclonal antibody (mAb)
Target/Biomarker	Hydrochlorothiazide (DCT)
Expression platform	Hybridoma
Isotypes	Mouse IgG
Bioactivity validation	Hydrochlorothiazide (DCT) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in DCT level test of Cardiovascular disease (high blood pressure) and related syndrome evaluation.
Tag	mFc
Products description	Competitive immunoassay-validated hapten-carrier conjugates BSA-Hydrochlorothiazide (DCT) / OVA-Hydrochlorothiazide (DCT) is Synthetic.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA),Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Target/Biomarker information

1. What is Hydrochlorothiazide, and What Role Does it Play in In Vitro Diagnosis (IVD)? Hydrochlorothiazide (HCTZ) is a widely used pharmaceutical compound classified as a thiazide diuretic. Thiazide diuretics are medications that promote diuresis, or the elimination of excess salt and water from the body through urine. In the context of in vitro diagnosis (IVD), Hydrochlorothiazide holds a pivotal position as an analyte with significant clinical implications, especially in the management of hypertension (high blood pressure). Role in IVD: Hypertension Management: Hypertension, or high blood pressure, is a prevalent and critical health condition affecting millions worldwide. Hydrochlorothiazide is a mainstay medication in the treatment and management of hypertension. Within the realm of IVD, various assays and tests are employed to quantify Hydrochlorothiazide levels in biological samples, such as blood or urine. These measurements serve a crucial role in monitoring the response of hypertensive patients to treatment. Treatment Efficacy Assessment: The quantification of Hydrochlorothiazide through IVD tests is essential for assessing the effectiveness of hypertension treatment. These tests allow healthcare professionals to monitor changes in drug levels over time, providing insights into how well the medication is controlling blood pressure. Dosing Optimization: Precise and individualized dosing of medications is a cornerstone of effective hypertension management. IVD procedures help optimize Hydrochlorothiazide dosages. By assessing drug concentrations, healthcare providers can fine-tune treatment plans, ensuring that patients receive the most suitable and effective doses tailored to their unique needs. 2. Why Measure Hydrochlorothiazide? Measuring Hydrochlorothiazide is instrumental for several key reasons: Treatment Evaluation: IVD assays for Hydrochlorothiazide are indispensable for evaluating the success of hypertension treatment. By quantifying the drug in patient samples, healthcare practitioners can gauge the therapeutic response and make informed decisions regarding treatment adjustments. This ongoing evaluation is crucial for maintaining blood pressure within a healthy range and preventing complications associated with hypertension. Patient Adherence Assessment: Monitoring Hydrochlorothiazide levels through IVD aids in the assessment of patient adherence to prescribed regimens. Deviations in drug concentrations may suggest non-compliance, prompting healthcare professionals to engage patients in discussions about medication adherence. This fosters open communication between patients and providers, ensuring that treatment plans are followed as prescribed. Side Effect Prevention: While Hydrochlorothiazide is an effective antihypertensive medication, it can potentially lead to side effects, particularly if dosage levels are inappropriate. IVD measurements help mitigate these risks by ensuring that patients remain within the therapeutic range, minimizing the likelihood of adverse reactions. This proactive approach promotes patient safety and well-being. Individualized Care: The era of personalized medicine emphasizes tailoring treatment strategies to the unique needs of each patient. IVD assays for Hydrochlorothiazide facilitate this approach by allowing healthcare providers to analyze drug levels in individual patients. This not only optimizes blood pressure management but also enhances overall therapeutic outcomes. In conclusion, the precise measurement of Hydrochlorothiazide through IVD procedures is indispensable for evaluating treatment efficacy, ensuring patient compliance, preventing adverse effects, and delivering individualized care to individuals dealing with hypertension. This approach enhances the quality of healthcare and contributes to improved patient outcomes in the management of high blood pressure and associated conditions. By combining pharmacological insights with advanced diagnostic tools, healthcare professionals can provide more effective and patient-centric hypertension management.

About GDU